NVCT · CIK 1875558
What Nuvectis Pharma, Inc. told the SEC could break it.
Nuvectis Pharma's risks are those of a clinical-stage biotech built on borrowed assets and a fragile supply chain. Its entire pipeline is licensed from third parties — the University of Edinburgh, Cancer Research Technology and the Institute of Cancer Research — under agreements carrying milestone payments of up to $279.5 million plus royalties, so losing a license would gut its pipeline. The supply behind its lead candidate, NXP900, is single-threaded: one sole-source manufacturer makes the drug substance and another the finished product, with no assured success; and as a clinical-stage company it depends on FDA and foreign regulatory approval, with the FDA possibly declining to accept data from trials run outside the U.S. and forcing additional costly trials.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- single sole-source CMOs for NXP900 drug substance and drug producthigh
Nuvectis relies on a single sole-source manufacturer for NXP900 drug substance and a separate single sole-source manufacturer for the finished drug product, with no assurance of successful manufacture.
“We currently rely, and expect to continue to rely, on third-party manufacturers for the production of drug substance and drug product for clinical trials in accordance with current Good Manufacturing Practices ("cGMPs"), including a single, sole source manufacturer to make the NXP900 drug substance and another single, sole source manufacturer to make the NXP900 finished drug product.”
SEC filing →As of 2026
Other disclosures
- pipeline IP licensed-in (Univ. of Edinburgh / CRT / ICR) with large milestone & royalty obligationsmedium
Nuvectis's entire pipeline is licensed from third parties (University of Edinburgh, Cancer Research Technology, Institute of Cancer Research) under agreements carrying milestone payments up to $279.5M plus tiered royalties; loss of a license would gut the pipeline.
“regulatory approval and commercial sales milestones of up to $279.5 million;”
SEC filing →As of 2026
Regulatory & policy
- FDA / foreign regulatory approval and acceptance of foreign trial datamedium
As a clinical-stage company, Nuvectis depends on FDA and foreign regulatory approval; the FDA may not accept data from trials conducted outside the U.S., potentially requiring additional costly U.S. trials.
“We cannot guarantee that the FDA or comparable foreign regulatory authority will accept data from trials conducted in whole or in part outside of the United States, which may result in the need for additional trials conducted in the United States.”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch